PMID- 37875427
OWN - NLM
STAT- MEDLINE
DCOM- 20231031
LR  - 20231031
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 45
IP  - 10
DP  - 2023 Oct 23
TI  - [Efficacy and safety of Anlotinib in the treatment of advanced sarcoma].
PG  - 904-910
LID - 10.3760/cma.j.cn112152-20210820-00632 [doi]
AB  - Objective: Patients with advanced sarcomas have a dismal prognosis with few 
      effective therapies. The purpose of this study was to evaluate the efficacy and 
      safety of anlotinib in the treatment of advanced sarcoma and to explore the 
      relationship between adverse events (AEs) and efficacy. Methods: Data from 45 
      advanced sarcoma patients who received anlotinib monotherapy at Affiliated Cancer 
      Hospital of Zhengzhou University between June 2018 and August 2021 were 
      retrospectively analyzed. According to Response Evaluation Criteria In Solid 
      Tumors (RECIST) Version 1.1, the objective remission rate (ORR) and disease 
      control rate (DCR) were calculated, and the progression free survival (PFS) and 
      treatment-related AEs were recorded and analyzed. Survival analysis was conducted 
      using the Kaplan-Meier survival rates were compared using the Log rank test. 
      Results: Forty patients were treated for more than 1.5 months and received 
      efficacy evaluation. The ORR and DCR after 3 months were 7.5%(3/40) and 
      80.0%(32/40), respectively. The overall ORR was 2.5%(1/40), the total DCR was 
      27.5%(11/40), and the median progression-free survival (m-PFS) was 6.70 months; 
      The m-PFS of alveolar soft tissue sarcoma (ASPS) was 10.27 months, which was 
      significantly longer than that of other subtypes of sarcoma (P=0.048). In 
      addition, the DCR of ASPS and synovial sarcoma (SS) was significantly better than 
      that of osteosarcoma (P<0.05). The most common AEs were elevated thyroid 
      stimulating hormone (17.8%, 8/45), anemia (15.6%, 7/45), fatigue (11.1%, 5/45). 
      Five patients developed grade 3 AEs after treatment; The PFS of patients with 
      hand-foot syndrome after treatment was significantly longer than that of patients 
      without hand-foot syndrome (14.10 vs 6.00, P=0.024). Conclusions: The efficacy of 
      anlotinib in the treatment of ASPS and SS is better than that of other subtypes. 
      The PFS in the group with hand-foot syndrome was significantly longer than that 
      of the group without hand-foot syndrome.
FAU - Yan, Q
AU  - Yan Q
AD  - Department of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou 450003, China.
FAU - Yao, W T
AU  - Yao WT
AD  - Department of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou 450003, China.
FAU - Du, X H
AU  - Du XH
AD  - Department of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou 450003, China.
FAU - Guo, L Y
AU  - Guo LY
AD  - Department of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou 450003, China.
FAU - Fan, Y C
AU  - Fan YC
AD  - Department of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou 450003, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - 0 (anlotinib)
SB  - IM
MH  - Humans
MH  - *Hand-Foot Syndrome
MH  - Retrospective Studies
MH  - *Sarcoma/drug therapy
MH  - *Sarcoma, Synovial/drug therapy
MH  - *Soft Tissue Neoplasms
MH  - *Bone Neoplasms
OTO - NOTNLM
OT  - Anlotinib
OT  - Efficacy
OT  - Osteosarcoma
OT  - Safety
OT  - Soft tissue sarcoma
EDAT- 2023/10/25 00:42
MHDA- 2023/10/31 06:42
CRDT- 2023/10/24 22:42
PHST- 2023/10/31 06:42 [medline]
PHST- 2023/10/25 00:42 [pubmed]
PHST- 2023/10/24 22:42 [entrez]
AID - 10.3760/cma.j.cn112152-20210820-00632 [doi]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2023 Oct 23;45(10):904-910. doi: 
      10.3760/cma.j.cn112152-20210820-00632.